<div id="readability-page-1"><p>China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $6.4650, but opened at $5.60. China SXT Pharmaceuticals shares last traded at $5.4010, with a volume of 69,414 shares traded.</p><h2>Analysts Set New Price Targets</h2><p>Separately, Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One analyst  has rated the stock with a Sell rating,  According to data from MarketBeat.com, China SXT Pharmaceuticals presently has a consensus rating of &#34;Sell&#34;.</p><p><b>Read Our Latest Research Report on SXTC</b></p><h2>China SXT Pharmaceuticals Stock Performance</h2><p>The stock has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.36. </p><p>China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter. </p><h2>Institutional Inflows and Outflows</h2><p>An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC grew its position in  China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Free Report) by 107.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,983 shares of the company's stock after acquiring an additional 15,013 shares during the quarter. Virtu Financial LLC's holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. Institutional investors and hedge funds own  5.02% of the company's stock. </p><h2>China SXT Pharmaceuticals Company Profile</h2> (Get Free Report)<p>China SXT Pharmaceuticals Inc <span>NASDAQ: SXTC<span></span></span> is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets. </p><p>The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than China SXT Pharmaceuticals</li><li>The day the gold market broke</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li><li>Gold’s getting scarce.</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?</h2><p>Before you consider China SXT Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.</p><p>While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SXTC

<p>China SXT Pharmaceuticals (NASDAQ:SXTC) shares gapped down from $6.4650 to $5.60 before trading on Tuesday, closing at $5.4010. Analysts have set a consensus rating of "Sell" for the stock, with Weiss Ratings reiterating a "sell (e+)" rating. The company reported a loss of ($4.50) EPS and revenue of $0.31 million for the last quarter. Institutional investor Virtu Financial LLC increased its stake in the company by 107.5%. China SXT focuses on peptide-based therapeutics for oncology and metabolic disorders.</p>

Market Beat

iShares US Pharma

China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Gap Down - Here's What Happened